ChinaBio Today -- Earnings week hit China biotech last week with a full-force onslaught, drowning out most of the normal newsflow. Two of the biggest US listed China biotech players, and several smaller companies, announced their first quarter results. Whether it was the economic crisis or just the unsettling winds of change in China medical delivery, the reports did not give evidence of triumphant achievement: overall, the results fell into the category of “decidedly mixed.”
